Bicycle Therapeutics Plc - ADR
BCYC
Get informed when a big investor buys or sells
+ FollowMarket Cap$267.86M
Close$
$-2.25
158.4% downside
Current Fair Value
158.4% downsideOvervalued by 158.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $267.86 Million |
|---|---|
| Enterprise Value | $-225,630,095.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.16 |
| Beta | 1.54 |
| Outstanding Shares | 69,804,828 |
Return
| Return on Equity | -37.32% |
|---|---|
| Return on Assets | -31.39% |
| Return on Invested Capital | -37.98% |
Valuation & Multiples
| P/E Ratio | -1.41 |
|---|---|
| PEG | 3.9 |
| Price to Sales | - |
| Price to Book Ratio | 0.55 |
| Enterprise Value to Revenue | -3.69 |
| Enterprise Value to EBIT | 1.06 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | -0.07 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.56
Average shareholder expectationRevenue Estimate
$4.77 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.40
Average shareholder expectationRevenue Estimate
$12.22 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.4324▼ 890.10% |
|---|---|
| Total Calls | 135,300▲ 342.16% |
| Total Puts | 329,100▼ 5.10% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 53.37%▼ 0.39% |
|---|---|
| Total Invested | $157.88M▼ 9.05% |
| Investors Holding | 112▲ 9.00% |
ESG Score
No data
About Bicycle Therapeutics Plc
CEO: Kevin Lee